Babies with leukemia could get an array of new treatments after scientists used genetic engineering to reproduce a gene defect found in the disease.
Acute myeloid leukemia is a high-risk cancer which affects children under two.
Scientists first pinpointed a biomarker linked to the cancer about twenty years ago.
Now for the first time they’ve used genetic engineering to make a model of the glitch which means they can study its biological mechanisms to unravel potential drug targets.
“This is the first step towards finding a cure for this rare but deadly form of childhood leukemia,” said Dr. Sabrina Tosi at Brunel University London.
“By generating an in vitro model for this type of leukemia, we are providing a tool for further investigation. It has enabled us to identify potentially druggable targets leading to possible new treatment. ”
Every year in the U.K. about 100 children are diagnosed with acute myeloid leukemia. And there’s no single “go to” treatment—doctors try different combinations of chemotherapy and bone marrow (stem cell) transplantation. Nearly no young children survive longer than three years.
Too much of the gene MNX1 product is found in infants with acute myeloid leukemia carrying a particular gene alteration Dr. Tosi discovered in 2000. But because the disease mainly affects babies, it is difficult to collect enough cancerous cells from the patients to study, so researchers know little about how the gene works. Her team has used gene editing to make a cellular model containing the genetic alteration that over-produces MNX1 that can be recreated over and over again. This means scientists can now study it intensely to see how it works at a molecular level, which will help highlight new treatments.
“Thanks to recent advances in genome engineering technologies, novel murine and human models have been developed,” says the study published in the journal Oncogenesis. “Mechanisms of leukemogenesis are therefore beginning to be uncovered, including the exact developmental window affected and the role of MNX1. Understanding the cytogenetic, molecular, and clinical features of t(7;12) will pave the way towards targeted therapeutic interventions.”
Source: Read Full Article